Key facts
- This page summarizes Mark Eisner's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jul 2024, 16:40.
Mark Eisner - 15 Jul 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)
- Reporting relationship
- EVP and Chief Medical Officer
- Issuer ticker
- VIR
- Reported as of
- 15 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2024, 16:40:36 UTC
- Prior SEC filing
- 03 Jun 2024
- Next SEC filing
- 25 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vanina de Verneuil, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Eisner filed Form 4 for Vir Biotechnology, Inc. (VIR) on 16 Jul 2024.
Change
- Previous filing in this sequence was filed on 03 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 15 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 150,000
- Date
- 15 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $9.37
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
Footnote F2
25% of the shares subject to the stock option vest and become exercisable on July 15, 2025, and the remainder vest in 36 equal monthly installments thereafter.